INFU InfuSystem Holdings, Inc Insider Trading

Director Paul Gendron purchases 5,000 shares on open market while stock trades well below 52-week highs; second open-market buy in 36 months.

Paul Gendron, a company director, is making a second open-market purchase of shares in InfuSystem, adding to a single prior buy from earlier in the 36-month window. The stock is currently trading well below its 52-week high, having declined significantly over the past month, creating a price environment where repeat insider buying typically occurs. InfuSystem remains profitable with growing revenue, trading at a moderate valuation—the type of fundamentals that might justify director confidence during a pullback. However, the timing of Gendron's prior open-market purchase revealed conflicting results: the stock fell slightly in the near term after that buy but recovered and gained over a longer three-month horizon. The current purchase at lower prices suggests he may be adding to a position he viewed favorably before, though the mixed outcomes from his previous trade mean this is not a pattern of flawless market timing.

INFU's President & CEO Carrie Lachance purchases 3,000 shares in two tranches amid broad insider buying and stock weakness.

Carrie Lachance, INFU's President and CEO, acquired 3,000 shares across two purchases within a three-day window. This activity is part of a broader wave of insider buying at InfuSystem, with three insiders purchasing shares in the same two-week period. The CEO is buying at a time when the stock trades well below its 52-week high and has declined sharply over the past month, suggesting purchases during a pullback. Notably, Lachance has a track record of well-timed buying at this company—her two prior open-market purchases over the past year were followed by material gains, establishing a pattern of buying into weakness that subsequently recovers. The underlying company remains fundamentally sound, posting year-over-year revenue growth and profitability, which provides a foundation for this buying activity. This is Lachance's third and fourth open-market purchase in the 36-month window, indicating a consistent pattern of share acquisition rather than a one-time event.

CFO Barry Steele buys 7,000 shares as stock trades well below 52-week high; repeat buyer with mixed prior timing.

Barry Steele, the company's Executive VP and CFO, is making his fourth open-market purchase in the past three years, adding 7,000 shares while InfuSystem's stock trades roughly one-fifth below its 52-week high and has declined over the past month. The company is profitable with growing revenue, making this a financially healthy backdrop for an insider purchase at a lower price point. However, Steele's prior three purchases at this stock show mixed results: two of them were well-timed and saw the stock rise afterward, but one recent buy in early March saw the stock decline in the following months, suggesting his timing has not been consistently reliable. This current purchase notably comes while the stock is in relative weakness, a pattern often associated with insider confidence, though his recent track record at this ticker warrants watching to see whether this trade proves to be well-timed or repeats the more recent miss.